Microvascular dysfunction and heart failure with preserved ejection fraction

Heart Failure

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

JACC Heart Fail

Siqueira SRO, Pabon MA, Vaduganathan M, Claggett BL, Lam CSP, Kosiborod MN, de Boer RA, Shah SJ, Fang JC, Desai AS, Jhund PS, Inzucchi SE, Martinez F, Hernandez AF, Petersson M, McMurray JJV, Solomon SD, Vardeny O

doi: 10.1016/j.jchf.2025.102585

Heart Failure

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF

Circ Heart Fail

Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Borentain M, Rohwedder K, Dayoub R, De Sanctis Y, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1161/CIRCHEARTFAILURE.125.013201

Heart Failure

Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes

JACC Heart Fail

Harrington J, Giczewska A, Rao VN, Fudim M, Peters AE, Chrischilles E, Jones WS, May H, Steinberg BA, VanWormer J, Cyr DD, Felker GM

doi: 10.1016/j.jchf.2025.102768

Heart Failure

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Eur J Heart Fail

Malgie J, Wilde MI, Koudstaal S, Denham R, da Fonseca CA, Swart HP, van Ofwegen CEE, Yilmaz A, Pisters R, Linssen GCM, Faber N, van Heerebeek L, van de Swaluw JEC, de Boer RA, Brunner-La Rocca HP, Brugts JJ

doi: 10.1002/ejhf.70006

Heart Failure

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JACC Heart Fail

Lu H, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Voors AA, Senni M, Zannad F, Pitt B, Shah SJ, Lam CSP, Scheerer MF, Scalise A, Mueller K, Berger M, Goea L, McMurray JJV, Solomon SD

doi: 10.1016/j.jchf.2025.102590

Heart Failure

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme

Eur J Heart Fail

Pandey A, Moroney M, Verma S, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Petrie MC, Rönnbäck C, Domdey A, Rasmussen S, Chinnakondepalli KM, Patel S, Kosiborod MN

doi: 10.1002/ejhf.70049

Heart Failure

The impact of country income level on the management of heart failure with preserved ejection fraction: an international survey

ESC Heart Fail

Ingimarsdóttir IJ, Saldarriaga C, Nielsen NCR, Einarsson H, Goldfeder S, Mewton N, Barasa A, Basic C, Oerlemans MIFJ, Niederseer D, Braun OÖ, Shchendrygina A, Gustafsson F, Ruschitzka F, Guidetti F, Kida K, Mohty D, Rakotonoel RR, Tun HN, Teng TK, Lam CSP, Vishram-Nielsen JKK

doi: 10.1093/eschf/xvag031

Heart Failure

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Eur Heart J

Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F

doi: 10.1093/eurheartj/ehaf655

Heart Failure

Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction

Circ Heart Fail

Kodur N, Gunsalus P, Milinovich A, Dalton JE, Tang WHW

doi: 10.1161/CIRCHEARTFAILURE.125.013386

Related content

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF

Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme

The impact of country income level on the management of heart failure with preserved ejection fraction: an international survey

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction